Subscribe to RSS

You must select a month AND year to filter.

Patients

• Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
• April 25, 2013
• The increasing cost of treatments for chronic myeloid leukemia in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today.

• ASH Awards First Bridge Grants to Sustain Critical Hematology Research During Current Period of Funding Restrictions
• April 8, 2013

• The American Society of Hematology (ASH), the world’s largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health (NIH). The announcement coincides with the Society’s participation as a Platinum Supporter in the “Rally for Medical Research,” held today in Washington, which will unite millions of Americans across the country to call on our nation’s policymakers to make medical research a national priority.

• Stillbirth or Pre-Term Birth Outcomes Linked to Elevated Risk of Blood Clots After Pregnancy
• April 2, 2013

• Newly identified pregnancy-related events, such as stillbirth or pre-term birth, may dramatically increase a woman’s risk of developing a potentially deadly blood clot immediately after pregnancy, according to the results of a large, population-based study published online today in Blood, the Journal of the American Society of Hematology (ASH).

• Cord Blood Transplants May Be An Effective Alternative to Matched Donor Stem Cells For Children with Rare Metabolic Disorder
• March 14, 2013

• Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler’s syndrome (HS), according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

• FDA Alerts Health Care Providers of Recall of Anemia Drug Omontys (FDA News)
• February 25, 2013

• The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill. The recall is due to reports of anaphylaxis, a serious and life-threatening allergic reaction. Omontys is used to treat anemia in adult dialysis patients.

• Risk of Leukemia After Cancer Chemotherapy Persists
• February 14, 2013

• While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

• Global number of Hematopoietic Stem Cell Transplants (HSCTs) hits 1 million
• February 4, 2013
• One million hematopoietic stem cell transplants (HSCTs) have been performed worldwide, according to data from the Worldwide Network for Blood and Marrow Transplantation (WBMT).

• FDA Approves Gleevec for Children with Acute Lymphocytic Leukemia (FDA News)
• January 29, 2013
• The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

• FDA Approves Octaplas to Treat Patients with Blood Clotting Disorders (FDA News)
• January 23, 2013
• The U.S. Food and Drug Administration today approved Octaplas, a pooled plasma (human) blood product for the replacement of clotting proteins (coagulation factors) in certain medical conditions where patients have insufficient levels. Clotting protein deficiencies can cause excessive bleeding or excessive clotting.

• ASH International Clinical Collaboration Replicates High Cure Rate of APL in Developing Countries
• January 14, 2013
• Data published online today in Blood, the Journal of the American Society of Hematology (ASH) describe the work of an ASH international clinical network collaborative focused on modernizing treatment protocols for patients in the developing world with acute promyeloctyic leukemia (APL) that has drastically improved cure rates in patients in Central and South America, achieving comparable outcomes to those observed in patients in the United States and in Europe.

• Cultural, Social Factors Identified As Barriers to Participation by Minorities in Unrelated Stem Cell Donation Registries
• December 20, 2012
• New research examining the role of race and ethnicity in an individual’s decision to become a donor for hematopoietic cell transplantation identifies several factors associated with varied participation rates in national donor registries across racial/ethnic groups.

• Daily Aspirin May Help Those at Risk for Recurrent Blood Clots (U.S. News & World Report)
• November 7, 2012

• About a quarter of people who experience the dangerous blood clots in the legs or lungs known as venous thromboembolisms (VTEs) develop them for no discernable reason, and most will receive a powerful anti-clotting drug such as warfarin in the months after the clot forms.

  But what about longer-term care, to ward off a recurrent clot, or events such as heart attack or stroke? A new study suggests that patients who go on low-dose daily aspirin after they are weaned off more powerful anticoagulants can derive real benefit.

• Blood or Bone Marrow Better for Stem Cell Transplants? (U.S. News)
• October 18, 2012
• For people whose bone marrow has been destroyed by chemotherapy, radiation or disease, stem cell transplants offer a potential lifeline back to health. But a key question has remained unanswered: Is it better to get the stem cells from a donor's blood or from bone marrow?

• Rare Cancers Yield Potential Source Of Tumor Growth (NIH News)
• September 18, 2012

• Researchers at the National Institutes of Health have discovered a genetic mutation that appears to increase production of red blood cells in tumors. The discovery, based on analysis of tissue from rare endocrine tumors, may help clarify how some tumors generate a new blood supply to sustain their growth, the researchers explained.

• Study Suggests New Approaches to Burkitt Lymphoma (NIH News)
• September 17, 2012

• A new study revealed insights into how Burkitt lymphoma differs from other lymphomas. The researchers identified several cancer-related genes and pathways that could serve as targets for future treatments.

< Prev Next > Page 1 of 9